Donanemab-azbt (Kisunla) is administered by intravenous infusion every four weeks and can rarely cause a life-threatening allergic reaction and swelling.
Sources
- Dementia - Diagnosis and treatment (mayoclinic.org)
- https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-adults-alzheimers-disease (fda.gov)
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761248s004lbl.pdf (accessdata.fda.gov)
- https://www.drugs.com/pro/kisunla.html (drugs.com)
More in Science
- The article on NASA's InSight mission has the DOI 10.1038/s41467-020-15251-7.
- Recipients of mechanical heart valves need lifelong blood thinners to prevent blood clots, whereas biological tissue valves made from cow, pig, or human heart tissue break down over time and may eventually need replacement.
- The first observation of above-threshold ionization was made using xenon gas.
- Across both phase 3 trials of protein subunit RSV vaccines, no deaths due to RSV respiratory illness were identified among either vaccine recipients or placebo recipients.
- 'The history and future of dietary guidance in America' has six listed authors: Lisa Jahns, Wendy Shaw, Alice Lichtenstein, Suzanne Murphy, Zachary Conrad, and Forrest Nielsen.
- On Nov. 4, 2022, the Centers for Disease Control and Prevention released an updated guideline for clinicians treating adult outpatients with short- and long-term pain, replacing its 2016 Guideline for Prescribing Opioids for Chronic Pain.